Key facts
- Notable investors include Frees Fund, Yongkan Investment.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Shanghai Boyin Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Shanghai Boyin Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Shanghai Boyin Biotech
Developer of non-viral vector-based therapies designed for genetic and chronic disease treatment. The company mainly develops non-viral vector gene therapy, focusing on solving the three major pain points of vector capacity limitation, non-repeatable administration, and high production cost in the field, and devoting itself to global gene therapy.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2020
- Ownership
- Privately Held (backing)
Shanghai Boyin Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Shanghai Boyin Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Shanghai Boyin Biotech in its N-PORT filings yet. We sweep new filings monthly.